Chapter 4
Expression, Detection, and Implication of ABC Proteins in Acute Myeloblastic Leukemia
Ollivier Legrand,
Ruo-Ping Tang,
Jean-Pierre Marie,
Ollivier Legrand
Inserm, UMRs 872, Paris, France
Département d'Hématologie et d'Oncologie médical, Hôtel-Dieu, Assistance Publique des Hôpitaux de Paris, Paris, France
Search for more papers by this authorRuo-Ping Tang
Inserm, UMRs 872, Paris, France
Département d'Hématologie et d'Oncologie médical, Hôtel-Dieu, Assistance Publique des Hôpitaux de Paris, Paris, France
Search for more papers by this authorJean-Pierre Marie
Inserm, UMRs 872, Paris, France
Département d'Hématologie et d'Oncologie médical, Hôtel-Dieu, Assistance Publique des Hôpitaux de Paris, Paris, France
Search for more papers by this authorOllivier Legrand,
Ruo-Ping Tang,
Jean-Pierre Marie,
Ollivier Legrand
Inserm, UMRs 872, Paris, France
Département d'Hématologie et d'Oncologie médical, Hôtel-Dieu, Assistance Publique des Hôpitaux de Paris, Paris, France
Search for more papers by this authorRuo-Ping Tang
Inserm, UMRs 872, Paris, France
Département d'Hématologie et d'Oncologie médical, Hôtel-Dieu, Assistance Publique des Hôpitaux de Paris, Paris, France
Search for more papers by this authorJean-Pierre Marie
Inserm, UMRs 872, Paris, France
Département d'Hématologie et d'Oncologie médical, Hôtel-Dieu, Assistance Publique des Hôpitaux de Paris, Paris, France
Search for more papers by this authorBook Editor(s):Ahcène Boumendjel, Jean Boutonnat,
Jacques Robert,
Jean Boutonnat
Institut Jean Roget, Université Joseph Fourier, Grenoble, France
Hôpital Michallon de Grenoble, Grenoble, France
Search for more papers by this authorJacques Robert
Institut Bergonié, Université Victor Segalen, Bordeaux, France
Search for more papers by this authorFirst published: 15 June 2009
Series Editor(s): Binghe Wang,
Binghe Wang
Search for more papers by this authorSummary
This chapter contains sections titled:
-
Introduction
-
P-glycoprotein (P-gp) ABCB1
-
Breast cancer resistance protein (BCRP) ABCG2
-
Multidrug resistance associated protein (MRP1) ABCC1
-
Multidrug resistance associated protein (MRP1) ABCC3
-
ABCA3
-
Future perspectives
-
References
REFERENCES
- Juliano RL and Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152–162.
- Kartner N, Riordan JR, and Ling V. 1983. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221: 1285–1288.
- Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM et al. 1986. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381–389.
- Marie JP, Zittoun R, and Sikic BI. 1991. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586–592.
- Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ et al. 2004. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 6: 129–137.
- Higgins CF. 1992. ABC transporters: From microorganisms to man. Annu Rev Cell Biol 8: 67–113.
- Dean M, Rzhetsky A, and Allikmets R. 2001. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11: 1156–1166.
- Borst P and Elferink RO. 2002. Mammalian ABC transporters in health and disease. Annu Rev Biochem 71: 537–592.
- Sharom FJ. 2008. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9: 105–127.
- Marie JP. 2001. Drug resistance in hematologic malignancies. Curr Opin Oncol 13: 463–469.
- Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M et al. 2002. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 1: 696–702.
- Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA et al. 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537–3547.
- Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM. 2006. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219–234.
- Marie JP, Huet S, Faussat AM, Perrot JY, Chevillard S, Barbu V et al. 1997. Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris. Leukemia 11: 1086–1094.
- Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Währer DC, Ossenkoppele GJ et al. 1997. Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia 11: 1110–1118.
- Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF et al. 1996. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 56: 3010–3020.
- Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P et al. 1991. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708–712.
- Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS et al. 1999. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest oncology group study. Blood 94: 1086–1099.
- Legrand O, Perrot JY, Simonin G, Baudard M, and Marie JP. 2001. JC-1: A very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood 97: 502–508.
- Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et al. 1997. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. Blood 89: 3323–3329.
- den Boer ML, Pieters R, Kazemier KM, Rottier MM, Zwaan CM, Kaspers GJ et al. 1998. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 91: 2092–2098.
- Steinbach D, Furchtbar S, Sell W, Lengemann J, Hermann J, Zintl F et al. 2003. Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML. Leukemia 17: 470–471.
- Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972.
- Fojo T and Bates S. 2003. Strategies for reversing drug resistance. Oncogene 22: 7512–7523.
- McDevitt CA and Callaghan R. 2007. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 113: 429–441.
- List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R et al. 1993. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652–1660.
- Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U et al. 1997. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15: 1796–1802.
- Chauncey TR, Rankin C, Anderson JE, Chen I, Kopecky KJ, Godwin JE et al. 2000. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A southwest oncology group study 9617. Leuk Res 24: 567–574.
- Marie JP, Bastie JN, Coloma F, Faussat Suberville AM, Delmer A et al. 1993. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 7: 821–824.
- Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M et al. 1992. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10: 1730–1736.
- Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM et al. 1996. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 10: 1741–1750.
- Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP et al. 2005. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol 55: 91–99.
- Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY et al. 1996. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study. Blood 88: 1198–1205.
- Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A et al. 1998. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: Results of a randomized study. Br J Haematol 102: 1015–1024.
- Liu Yin JA, Wheatley K, Rees JK, and Burnett AK; UK MRC Adult Leukemia Working Party. 2001. Comparison of “sequential” versus “standard” chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial. Br J Haematol 113: 713–726.
- Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA et al. 2002. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100: 1224–1232.
- Solary E, Drenou B, Campos L, de Cremoux P, Mugneret F, Moreau P et al.; Groupe Ouest Est Leucemies Aigues Myeloblastiques. 2003. Quinine as a multidrug resistance inhibitor: A phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 102: 1202–1210.
- List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, and Slovak ML. 2001. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 98: 3212–3220.
- Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L et al. 2004. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J Clin Oncol 22: 1078–1086.
- Gerrard G, Payne E, Baker RJ, Jones DT, Potter M, Prentice HG et al. 2004. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89: 782–790.
- Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P et al. 2004. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 10: 3265–3272.
- Lancet JE, Gotlib J, Wetzler M, Luger S, Cripe LD, Tallman MS et al. 2007. Phase I/II study of the P-Glycoprotein (Pgp) inhibitor zosuquidar administered by continuous infusion (CIV) with daunorubicin (DNR) and cytarabine (ARA-C) as primary therapy in older patients with Pgp-positive acute myeloid leukemia (AML). Blood (ASH Annual Meeting Abstracts) 110 (November): 299.
- Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H et al. 1999. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91: 429–433.
- Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, and Dean M. 1998. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58: 5337–5339.
- Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B et al. 1999. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res 59: 8–13.
- Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH et al. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61: 3458–3464.
- Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP et al. 2004. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10: 7896–7902.
- Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, and Sauerbrey A. 2002. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16: 1443–1447.
- Uggla B, Stahl E, Wagsater D, Paul C, Karlsson MG, Sirsjo A et al. 2005. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 29: 141–146.
- Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A et al. 2006. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 91: 825–828.
- Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, and Chaoui D. 2005. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 11: 7764–7772.
- Plasschaert SL, van der Kolk DM, de Bont ES, Kamps WA, Morisaki K, Bates SE et al. 2003. The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res 9: 5171–5177.
- Sauerbrey A, Sell W, Steinbach D, Voigt A, and Zintl F. 2002. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 118: 147–150.
- Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD et al. 2004. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 18: 78–83.
- Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Ford LA, Greco WR et al. 2004. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: Frequent expression and possible correlation with shorter disease-free survival. Br J Haematol 127: 392–398.
- Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, and Taylor CG. 2001. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 115: 257–262.
- Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, and Sorrentino BP. 2002. Low levels of ABCG2 expression in adult AML blast samples. Blood 100: 4594–4601.
- van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, van der Holt B et al. 2002. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 16: 833–839.
- van der Kolk DM, Vellenga E, Scheffer GL, Müller M, Bates SE, Scheper RJ et al. 2002. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99: 3763–3770.
- van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE et al. 2007. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 86: 329–337.
- Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654.
- Legrand O, Simonin G, Perrot JY, Zittoun R, and Marie JP. 1998. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91: 4480–4488.
- Schaich M, Soucek S, Thiede C, Ehninger G, and Illmer T. 2005. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 128: 324–332.
- Laupeze B, Amiot L, Drenou B, Bernard M, Branger B, and Grosset JM. 2002. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 116: 834–838.
- Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, and Marie JP. 1999. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 94: 1046–1056.
- Borg AG, Burgess R, Green LM, Scheper RJ, and Yin JA. 1998. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 103: 1083–1091.
- van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE et al. 2000. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 6: 3205–3214.
- Filipits M, Suchomel RW, Zochbauer S, Brunner R, Lechner K, and Pirker R. 1997. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome. Clin Cancer Res 3: 1419–1425.
- Legrand O, Zittoun R, and Marie JP. 1999. Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia 13: 578–584.
- Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N et al. 2007. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group. Leukemia 21: 66–71.
- Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, and Linenberger ML. 2003. Multidrug resistance protein attenuates gemtuzumab ozogamicininduced cytotoxicity in acute myeloid leukemia cells. Blood 102: 1466–1473.
- Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, and Mehta AB. 1994. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia 8: 2163–2168.
- de Boekhorst PA, Lowenberg B, van Kapel J, Nooter K, and Sonneveld P. 1995. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 9: 1025–1031.
- Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE et al. 1995. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85: 186–193.
- Zhou DC, Zittoun R, and Marie JP. 1995. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 9: 1661–1666.
- Lohri A, van Hille B, Bacchi M, Fopp M, Joncourt F, Reuter J et al. 1997. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss group for Clinical Cancer Research (SAKK). Eur J Haematol 59: 206–215.
- Olson DP, Taylor BJ, La M, Sather H, Reaman GH, and Ivy SP. 2005. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: A retrospective study of 295 newly diagnosed patients by the Children's Oncology Group. Leuk Lymphoma 46: 681–691.
- Damiani D, Michelutti A, Michieli M, Masolini P, Stocchi R, Geromin A et al. 2002. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. Br J Haematol 116: 519–527.
- Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, and Sauerbrey A. 2003. Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res 9: 1083–1086.
- Steinbach D, Wittig S, Cario G, Viehmann S, Mueller A, Gruhn B et al. 2003. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 102: 4493–4498.
- Plasschaert SL, de Bont ES, Boezen M, van der Kolk DM, Daenen SM, Faber KN et al. 2005. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 11: 8661–8668.
- Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ et al. 1999. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A 96: 6914–6919.
- Zelcer N, Saeki T, Reid G, Beijnen JH, and Borst P. 2001. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276: 46400–46407.
- Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A et al. 2004. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64: 1403–1410.
- Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. 2004. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101: 14228–14233.
- Norwood K, Wang RY, Hirschmann-Jax C, Andreeff M, Brenner MK, Goodell MA et al. 2004. An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res 28: 295–299.
- Wulf GG, Modlich S, Inagaki N, Reinhardt D, Schroers R, Griesinger F et al. 2004. ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica 89: 1395–1397.
- Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V et al. 2006. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 12: 4357–4363.
- Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, et al. 2008. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 22: 1576–1586.
- Yamano G, Funahashi H, Kawanami O, Zhao LX, Ban N, Uchida Y et al. 2001. ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett 508: 221–225.
- Efferth T, Gillet JP, Sauerbrey A, Zintl F, Bertholet V, de Longueville F et al. 2006. Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther 5: 1986–1994.
- Steinbach D and Legrand O. 2007. ABC transporters and drug resistance in leukemia: Was P-gp nothing but the first head of the Hydra? Leukemia 21: 1172–1176.
- Raaijmakers MH. 2007. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia 21: 2094–2102.
- Ross DD and Doyle LA. 2004. Mining our ABCs: Pharmacogenomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell 6: 105–107.
